← Human Trials & Peer-Reviewed Studies
Inflammatory acne management with a novel prescription dietary supplement
Plain-language guide to PMID 23377512 (2012): open-label and multicenter clinical trial study of Copper (Supplement) in 235 patients, acne.
Key Facts
- PMID
- 23377512
- Journal
- Journal of drugs in dermatology : JDD
- Year
- 2012
- Study type
- Clinical Trial
- Authors
- Shalita AR et al. (9 authors)
What This Study Did, in Plain Language
What Was Tested
This clinical trial paper looks at Copper (Supplement) in the context of acne.
To assess the usefulness of a novel dietary supplement in the overall management of patients with inflammatory acne vulgaris.
Why It Was Studied
Long-term acne treatment with such drugs, however, is frequently accompanied by undesirable adverse reactions, including gastrointestinal disturbances, antianabolic effects, headaches, tinnitus, and photosensitivity.
Who Took Part
According to the abstract, 235 patients were involved.
PubMed indexes the participants as children, teenagers, young adults, adults and middle-aged adults, both men and women.
235 patients with inflammatory acne vulgaris were enrolled by dermatologists in a multicenter, open-label, 8-week, prospective study evaluating the effects of adding NicAzel, 1 to 4 tablets daily, to their current acne treatment regimen.
How the Study Was Run
In design terms this was a open-label and multicenter study.
Nothing was hidden in this open-label Copper (Supplement) study: the patients and staff both knew the treatment.
More than one site took part, so the patients came from several places.
What Was Measured
Long-term acne treatment with such drugs, however, is frequently accompanied by undesirable adverse reactions, including gastrointestinal disturbances, antianabolic effects, headaches, tinnitus, and photosensitivity.
Topics PubMed links to this paper include Acne Vulgaris, Anti-Bacterial Agents, Copper, Dicarboxylic Acids, Dietary Supplements, Folic Acid and Inflammation.
What This Means in Plain Language
The paper is an open-label and multicenter study of Copper (Supplement) in 235 patients in people with acne.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2012 (Journal of drugs in dermatology : JDD), a journal based in United States.
More context: the Copper (Supplement) compound page, Acne research.
Our Notes on the Compound
Copper (Supplement): The active site of cytochrome c oxidase is described as containing copper ions that are essential for electron transfer.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.